Hello, welcome to the Verona Pharmaceuticals Annual General Meeting 2021. All participants will be in the listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your touch-tone phone. To withdraw your question, please press star then two. Please note, today's event is being recorded. I now turn the conference over to Dr. David Ebsworth. Dr. Ebsworth, please go ahead. Thank you very much. Good day, ladies and gentlemen. It is my pleasure as chairman to welcome you to the Verona Pharma plc Annual General Meeting. I am joined today by telephone by our non-executive directors, our Chief Executive Officer, Dr. David Zaccardelli, our Chief Financial Officer, Mark Hahn, our General Counsel, Claire Poll, our Company Secretary, Ben Harber, and representatives from our auditors, PwC. At this time, all participants are in a listen-only mode. At the end of the meeting, we will hold a Q&A session, during which we will answer questions relevant to the business of the company and the meeting's matters. As noted in our AGM notice, each shareholder is limited to two questions. Questions should be succinct and only cover a single topic. If it is not possible to answer any of the questions submitted during the meeting, we will endeavor to respond to those questions after the meeting. We note that the company will be hosting a further conference call on Thursday the 29th of April to present its first quarter 2021 financial results. This call will provide an opportunity for shareholders to receive an update on the company's financial results and operations and ask related questions. Details of the conference call are on the company's website under the Investors section. This annual general meeting of the company was convened by notice to shareholders dated the 19th of March 2021. The business of the meeting is to reelect myself, Dr. David Ebsworth, Dr. Martin Edwards, Dr. Anders Ullman, and Lisa Deschamps as directors of the company. To receive and adopt the 2020 U.K. Annual Report. To receive and approve the U.K. Directors' Remuneration Report. To receive and approve the U.K. Directors' Remuneration Policy. To appoint PricewaterhouseCoopers LLP as auditors. To authorize the Audit and Risk Committee to determine the auditors' remuneration for the year ending December 31st, 2021. To authorize the directors to allot securities and to disapply preemption rights on allotment of securities. May I take the notice as read? We will now move to the formal business of the meeting, and it's proposed we deal with each of the resolutions by way of poll vote. I therefore exercise my right as chairperson of the meeting, in accordance with the company's articles of association, to call for a poll vote on all of the resolutions set out in the notice of the meeting using the final proxy voting figures received by the company secretary. Prior to the meeting, pre-populated poll cards using the final proxy voting numbers produced by the company secretary were completed and signed. I will now announce the results of the poll in percentage terms only. I will read the results of each resolution in turn. Resolution one. In favor, 99.996%. Against, 0.004%. I declare the resolution carried as an ordinary resolution. Resolution two. In favor, 99.995%. Against, 0.005%. I declare the resolution carried as an ordinary resolution. Resolution three. In favor, 99.996%. Against, 0.004%. I declare the resolution carried as an ordinary resolution. Resolution four. In favor, 99.986%. Against, 0.014%. I declare the resolution carried as an ordinary resolution. Resolution five. In favor, 99.997%. Against, 0.003%. I declare the resolution carried as an ordinary resolution. Resolution six. In favor, 99.858%. Against, 0.142%. I declare the resolution carried as an ordinary resolution. Resolution seven. In favor, 99.85%. Against, 0.15%. I declare the resolution carried as an ordinary resolution. Resolution eight. In favor, 99.996%. Against, 0.004%. I declare the resolution carried as an ordinary resolution. Resolution nine. In favor, 99.994%. Against, 0.006%. I declare the resolution carried as an ordinary resolution. Resolution 10. In favor, 90.699%. Against, 9.301%. I declare the resolution carried as an ordinary resolution. Resolution 11. In favor, 90.698%. Against, 9.302%. I declare the resolution carried as a special resolution. That completes the business of the annual general meeting, and I declare the formal business of the meeting closed. I will now turn the call over to the Operator for the question and answer session. Yes. Thank you. We will now begin the question- and- answer session. All right, sir, currently there are no questions on the phone. Okay. Well, in that case, perhaps I'll wrap up. Let me take this opportunity to thank our shareholders for your continued support. Let me also extend my thanks on behalf of the board to the management and our dedicated team of hardworking professionals who are dedicating themselves to bring ensifentrine, a new therapeutic alternative for patients suffering from chronic obstructive pulmonary disease, to the market. Thank you, Operator. That concludes today's call.